Urinalysis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Urinalysis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The urinalysis market is expected to exhibit a growth of 7.5% CAGR during the forecast period. The higher burden of chronic diseases and rising adaptation of point-of-care testing are expected to be the major contributing factors to the market growth. Urinary tract infection refers to an infection in any part of the urinary system.

The outbreak of COVID-19 impacted the urinanalysis market, as hospitals and healthcare services restricted services due to social distancing measures. The unprecedented increase in coronavirus-infected patients reduced access to other primary care services and resulted in a significant drop in non-COVID-19-related diagnoses, such as urinary tract infections or kidney diseases. According to a research article by Ahmed Al-Jabir et al., published in the International Journal of Surgery, July 2020, during the COVID-19 pandemic, urological procedures delayed or postponed included urinary tract infections, stress incontinence, overactive bladder (OAB), and neurogenic bladder. Thus, the postponement and cancelation of many elective surgeries negatively impacted the market at the beginning of 2020​. Similarly, according to a December 2020 study published in the ADIAN Journal, titled, “A significant decrease in Urinary tract infection (UTI) diagnoses due to the COVID-19 pandemic raises concern”, when people with COVID-19 were infected with SARS-CoV-2, the pandemic changed primary care dramatically. As per the same source, this resulted in fewer patients seeking primary care services and fewer diagnoses, including UTIs. The source also reports that between March 30 and April 24, 2020, the weekly rate of UTI diagnosis per 100,000 population fell from an average of 30-35 to less than 10 in England. Since April, the rate has risen by 50% of the usual rate. ​The increase in the rate of UTI diagnosis positively impacted market growth. Hence, it is observed that COVID-19 had a significant impact on the market studied in the initial year i.e. 2020, however, the market is expected to gain momentum shortly.

Additionally, the increasing burden of diabetes and the rising prevalence of chronic kidney diseases are some of the leading factors that are propelling growth of the market studied. For instance, as per a December 2021 update by the International Diabetes Federation (IDF), in 2021, approximately 537 million adults (20-79 years) had diabetes, which is projected to rise to 643 million by 2030 and 783 million by 2045. As per the same source, 3 in 4 adults with diabetes live in low- and middle-income countries and almost 1 in 2 (240 million) of them are undiagnosed. The source also reports that diabetes caused 6.7 million deaths in 2021. To identifiy the glucose level in diabetic people, urine analysis is proved to be an important test which is largely done across the diabetic patients in the world.

Hence, owing to the above-mentioned factors, the market studied is expected to witness strong growth over the forecast period. However, stringent refulatory framework is believed to hinder the market growth.

Key Market TrendsPregnancy & Fertility Segment is Expected to Hold a Major Market Share Over the Forecast Period

By checking the elevated amounts of sugars, proteins, ketones, and bacteria, a urine test can be used to diagnose diabetes, dehydration, kidney or bladder infections, and Preeclampsia. High sugar levels may be a sign of gestational diabetes, which may appear around week 20 of pregnancy. Human chorionic gonadotropin (hCG), a unique hormone that only arises in a woman's body during pregnancy, is what pregnancy tests seek. These tests can check for hCG in the blood or urine. Home urine tests for pregnancy are affordable and often used. Home pregnancy tests are fairly accurate when done correctly.

Several studies have been conducted to understand the accuracy of urinalysis to judge pregnancy. For instance, an article published in September 2021 by the National Institute of Health titled, 'Urine pregnancy testing: When does no mean maybe?' stated that in general, there are two possible causes for a patient to have an erroneously negative Urine Pregnancy Test (UPT). Early pregnancy cases where a patient may not produce enough human chorionic gonadotropin (hCG) to result in a positive test, a threshold that allegedly ranges from 15 to 100 mIU/mL, represent the first and most likely scenario. Secondly, the circumstance that may be more worrisome is patients who are farther along in their pregnancy and suffer the "hook effect," which is when elevated or excessive amounts of hCG overwhelm the urinary pregnancy test and cause a false negative. Despite the certain cases where urine tests provide negative results, it is considered the first line of diagnosis for pregnancy.

Furthermore, continuous new launches of pregnancy tests by key players are augmenting segment growth. For instance, in April 2022, Mankind Pharma launched a rapid testing pregnancy device that is used for urinalysis to confirm pregnancy.

Additionally, owing to the rising awareness across the general population, urine tests are performed largely in developing countries such as India and South Africa which is propelling the segment growth.

North America is Expected to Hold a Significant Share in the Market

North America is expected to hold a major market share in the global urinalysis market due to the increasing aging population and higher prevalence of chronic kidney diseases. Chronic kidney disease is associated with kidney failure. According to the 2021 data published by the National Kidney Foundation, chronic kidney disease causes more death than breast cancer and prostate cancer. Currently, around 37 million people are affected by it. It is more prevalent in an older population, affecting approximately 15% of the adult population. Hence, emerges the need for proper diagnosis and treatment of chronic kidney diseases, and thereby these factors are expected to boost the demand for the urinalysis market.

As per the article published by the National Center for Biotechnology Information in November 2020 titled, 'An introduction to the epidemiology and burden of urinary tract infections, the prevalence of uncomplicated urinary tract infections is high, and an estimated 40% of women in the United States are likely to develop a Urinary Tract Infection (UTI) during their lifetime. The World Population Ageing Report 2020 stated that, in the United States, the number of people aged above 65 is projected to reach 84,813 thousand by 2030, from 53,340 thousand in 2019, and the 65-and-older age group’s share in the total population may rise from 16.2% in 2019 to 22.4% by 2050. The prevalence of urological disorders increases with age which is propelling the market growth.

This indicates a big potential market demand for urinalysis, along with the rapid increase in the incidence and prevalence of kidney cancer. Thus, the market in the United States is expected to grow in the coming years.

Competitive Landscape

The Urinalysis Market is moderately competitive in nature due to the presence of few players operating globally as well as regionally. Companies are taking strategic initiatives to grow their presence in the urinalysis market. Currently, some of the major players includes, Cardinal Health Inc., Alere (Abbott Laboratories), Beckman Coulter Inc., Siemens Healthineers, Roche Diagnostics, Sysmex Corporation, Bio-Rad Laboratories Inc., Arkray Inc., Acon Laboratories Inc., and Becton, Dickinson, and Company.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.